Conditions: Secondary-progressive Multiple Sclerosis
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 8
Healthy volunteers: no

Brief summary:
To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.

Detailed description:
Multiple sclerosis (MS) is primarily a demyelinating disease of the central nervous system (CNS), but many patients also undergo progressive atrophy, especially in the gray matter (GM). GM atrophy plays a particularly prominent role in development of cognitive and physical disability in MS. Evidence is mounting that there is a profound infiltration of activated microglia and blood-borne macrophages throughout the lesions, whereas in slowly expanding (smoldering) or chronic active expanding lesions, the microglia and macrophages are concentrated as a dense rim around the lesions. Microglia is also activated, in a more diffuse way, in the white matter (WM) and GM with concomitant axonal degeneration and meningeal inflammation. Thus, chronic activation of microglia has been linked to neurodegeneration in the progressive phase of the disease and development of brain atrophy.

No longitudinal studies in MS examined the association between development of microglia-related pathology in patients treated with siponimod (Mayzent®). This will be the first study to examine the treatment effect of Mayzent on microglia in MS.

Arms:
arm 1: Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Ocrevus by their neurologist. arm 2: Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Mayzent by their neurologist.

Interventions: intervention 1: Mayzent intervention 2: Ocrevus
Intervention descriptions: intervention 1: PET imaging to evaluate the effects of Mayzent on the microglia of the brain. intervention 2: PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.

Protocol document:
Prot_SAP_ICF_000.pdf: 
Cover Page for Protocol, Statistical Plan and ICF
Official Title:
Open-label, single-blinded, observational, prospective, 36-
month, longitudinal, controlled study to assess the efficacy
of siponimod (Mayzent®) on microglia in patients with
secondary progressive forms of multiple sclerosis
NCT number:
NCT04925557
Document Type:
Study Protocol, Statistical Analysis Plan; Informed Consent
Forms (Main)
Date of the
Document:
Study Protocol: 3/3/2023
SAP: 9/15/2023
Consent Documents: 9/29/2022


 
University at Buffalo Institutional Review Board (UBIRB) 
Office of Research Compliance | Clinical and Translational Research Center Room 5018 
875 Ellicott St. | Buffalo, NY 14203 
UB Federalwide Assurance ID#: FWA00008824 
PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on 
microglia in patients with secondary progressive forms of multiple sclerosis  
Page 1 of 23
 
 
Local Supplement to Sponsor Protocol (HRP-508) 
 
INSTRUCTIONS:  
• Only use this form when also providing a protocol (not just a grant 
application) from a sponsor or lead site (e.g. commercial, NIH, etc.). 
For all other protocols use HRP-503. 
• Depending on the nature of your study, some sections may not be 
applicable to your research. If so, you must provide the reason why the 
section is not applicable. For example, when accurate, the statement, 
“local inclusion criteria will not differ from those of the sponsor’s
protocol” could be provided in response to question 1.1. 
• Provide the entire Sponsor protocol as a separate upload in Click IRB. 
• Unless otherwise specified, provide only site-specific information 
below. 
• When you write a single site supplement, keep an electronic copy. You 
will need to modify this copy when making changes. When you make 
changes, use the Track Changes feature. 
•  Do not remove the italics instructions or headings. 
• If you are pasting information from other documents be sure to use the 
"Merge Formatting" paste option so that the formatting of the 
response boxes is not lost.  If information is presented outside of the 
response boxes, it may not be accepted.  
• If this study involves multiple participant groups who participate in 
different research procedures, consent processes, etc., be certain to 
provide information in each applicable section for each participant 
group and clearly label each participant group within a section or 
subsection. 
 
PROTOCOL TITLE: 
Include the full protocol title. 
Response: Open-label, single-blinded, observational, prospective, 36-
month, longitudinal, controlled study to assess the efficacy of siponimod 
(Mayzent®) on microglia in patients with active secondary progressive 
forms of multiple sclerosis  


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 2 of 23 
IRB Version: 1/23/19 
PRINCIPAL INVESTIGATOR: 
Name 
Department 
Telephone Number 
Email Address 
Response:  
Robert Zivadinov 
Neurology 
716-859-7040 
rzivadinov@bnac.net 
 
 
FUNDING: 
Indicate any funding for this proposal. This should match the Funding Sources 
page in Click IRB. 
Response: Buffalo Neuroimaging Analysis Center 
 
GRANT APPLICABILITY: 
Describe whether or not this protocol is funded by a grant or contract and if so, 
what portions of the grant this study covers. 
Response: Not applicable. 
 
VERSION NUMBER/DATE: 
Include the version number and date of this site supplement. 
Response: 5, 03MAR23 
Revision History 
 
Revision
# 
Version Date 
Summary of Changes 
Consent 
Change? 
1 
24/06/2021 
Change based on the new study protocol 
Yes 
2 
28/02/22 
Addition of Dent Institute as a recruitment and 
testing site 
New MS 
consent 
for DENT; 
Yes to 
current 
MS 
consent 
form


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 3 of 23 
IRB Version: 1/23/19 
3 
07/04/2022 
Inclusion of 15 healthy controls to undergo 1 
PET scan and 1 MRI scan. 
New HC 
consent 
form 
4 
11/9/2022 
Including Great Lakes Medical Imaging as a 
PET scanning site 
No 
5 
03/03/2023 
Closing enrollment and follow-up of MS 
patients; Closure letter; continued enrollment 
of HCs 
Yes - HC 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 4 of 23 
IRB Version: 1/23/19 
Table of Contents 
1.0
Study Summary ........................................................................................................ 4
2.0
Study Intervention/Investigational Agent ................................................................ 7
3.0
Inclusion and Exclusion Criteria* ............................................................................ 8
4.0
Withdrawal of Subjects* .......................................................................................... 8
5.0
Vulnerable Populations* .......................................................................................... 9
6.0
Sharing of Results with Subjects* ........................................................................... 9
7.0
Setting .................................................................................................................... 10
8.0
Resources Available............................................................................................... 11
9.0
Prior Approvals ...................................................................................................... 13
10.0
Local Recruitment Methods ................................................................................... 13
11.0
Local Number of Subjects ..................................................................................... 14
12.0
Data Management and Confidentiality .................................................................. 15
13.0
Provisions to Protect the Privacy Interests of Subjects .......................................... 16
14.0
Compensation for Research-Related Injury ........................................................... 16
15.0
Economic Burden to Subjects ................................................................................ 17
16.0
Consent Process ..................................................................................................... 17
17.0
Process to Document Consent in Writing .............................................................. 22
18.0
Data and Specimen Banking* ................................................................................ 22
 
  
1.0 
Study Summary 
 
Study Title 
Open-label, single-blinded, observational, 
prospective, 36-month, longitudinal, 
controlled study to assess the efficacy of 
siponimod (Mayzent®) on microglia in 
patients with active secondary progressive 
forms of multiple sclerosis 
 
Study Design 
Open label, single-blinded, observation, prospective, 
longitudinal 
BNAC MRI analysts are blinded to subject’s medication
treatment.  
Primary Objective 
The assessment of the effect of Mayzent over at least 24 
months on the evolution of microglia pathology in patients 
with active secondary-progressive (SP) MS. 
Secondary 
Objective(s) 
(a) compare the effect of Mayzent to the control group 
of active SPMS patients treated with ocrelizumab 
(Ocrevus®), as measured by changes in microglial 
activation in the lesional and non-lesional normal 
appearing (NA) WM and GM, and in the peri-plaque 
area of chronic lesions in the brain; (b) the 
relationship between changes in microglial activation 
in the lesional and non-lesional normal appearing 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 5 of 23 
IRB Version: 1/23/19 
(NA) WM and GM, and in the peri-plaque area of 
chronic lesions in the brain and clinical and 
behavioral outcomes. 
(b) to validate the quantification approach and to use as 
a statistical control group (15 HCs) when looking at 
an increase in TSPO in a parametric map of the brain 
Research 
Intervention(s)/ 
Investigational 
Agent(s)  
MRI and PET scans, clinical visits, questionnaires, eye 
exam, blood sampling.  
IND/IDE #  
 
Study Population 
Individuals with active Secondary Progressive Multiple 
Sclerosis (SPMS) 
Activity is determined by MRI activity (contrast-enhancing 
lesions; new and unequivocally enlarging T2 lesions) and/or 
clinical relapses in the 24 months prior to the study baseline. 
 
15-age-matched healthy controls (10 females and 5 males 
aged between 18-65 years) 
Sample Size 
60 MS patients; 15 healthy controls 
Study Duration for 
individual 
participants 
2-3 years: MS Patients 
Approximately 4 hours: healthy controls – 1 timepoint 
Study Specific 
Abbreviations/ 
Definitions  
 
 
 
AEs 
Adverse Events 
BBB 
Blood-brain-barrier 
BICAMS 
Brief International Cognitive Assessment for MS 
BNAC 
Buffalo Neuroimaging Analysis Center 
BVMT-R 
Brief Visuospatial Memory Test – Revised 
CE 
Contrast Enhancing 
CNS 
Central Nervous System 
CRFs 
Clinical Research Forms 
CSF 
Cerebrospinal fluid 
CVLT-II 
California Verbal Memory Test – Second Edition 
3-D 
Three Dimensional 
EDSS 
Expanded Disability Status Scale 
ECG 
Electrocardiogram 
ELISA 
Enzyme-linked immunosorbent assay 
ETL 
Echo Train Length 
FLAIR
Fluid-Attenuated Inversion Recovery
FLIRT 
FMRIB’s Linear Image Registration Tool 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 6 of 23 
IRB Version: 1/23/19 
FMRIBs 
Functional MRI of the Brain 
FOV 
Field of View 
FSE 
Fast Spin Echo 
FSPGR 
Fast Spoiled Gradient Echo 
GFAP 
Glial fibrillary acidic protein 
GE 
General Electric 
GM 
Gray Matter 
GRE 
Gradient Echo Sequence 
HAB 
High affinity for DNA polymorphism of the TSPO gene on 
chromosome 22q13.2 SNP 
HD 
High Definition 
HDNV 
Head and Neck Neurovascular Coil 
HIPAA 
Health Insurance Portability and Accountability Act 
HIRES 
High Resolution 
IEC 
Independent Ethics Committee 
IR 
Inversion Recovery 
IRB 
Investigational Review Board 
IR-FSPGR 
Inversion Recovery-Prepared fast Spoiled Gradient Recalled 
Sequence 
ITT 
Intention-to-Treat 
LAB 
Low affinity for DNA polymorphism of the TSPO gene on 
chromosome 22q13.2 SNP 
LCLA 
Low contrast letter acuity 
LV 
Lesion volume 
MAB 
Co-expression of LAB and HAB affinity for DNA 
polymorphism of the TSPO gene on chromosome 22q13.2 
SNP 
MR 
Magnetic Resonance 
MRI 
Magnetic Resonance Imaging 
MS  
Multiple Sclerosis 
MTR 
Magnetization transfer ratio 
NA 
Normal appearing 
9-HPT 
Nine-Hole Peg test  
OCT 
Optical coherence tomography 
PBR 
Peripheral benzodiazepine receptor 
PBVC 
Percent brain volume change 
PCVC 
Percent cortical volume change 
PD 
Proton Density 
PET 
Position emission tomography 
PI 
Prescribing information 
PTVC 
Percent thalamic volume change 
RCP 
Radiochemical purity 
ROI 
Region of interest 
QSM 
Quantitative susceptibility mapping 
REB 
Research Ethics Board 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 7 of 23 
IRB Version: 1/23/19 
SAEs 
Serious Adverse Events 
SD 
Standard Deviation 
SDMT 
Symbol Digit Modalities Test 
SE 
Spin Echo 
SIENA 
Structural Image Evaluation, using Normalization of 
Atrophy 
SIENAX 
Structural Image Evaluation, using Normalization of 
Atrophy Cross-Sectional 
sNfL 
Serum neurofilament light chain 
SNP 
Single nucleotide polymorphism 
SPGR 
Spoiled Gradient Recalled Acquisition 
SPMS 
Secondary-progressive multiple sclerosis 
SPSS 
Statistical Package for the Social Sciences  
TE 
Echo Time 
TI 
Inversion Time 
T25FW 
Timed 25-Foot Walk  
TR 
Repetition Time 
TSPO 
18 kDa translocator protein 
USPIO 
Ultrasmall superparamagnetic iron oxide particles 
VOI 
Volume of interest 
VT 
Volume of distribution 
VZV 
Varicella zoster virus 
WB 
Whole Brain 
WI 
Weighted Image 
WM 
White Matter 
 
 
 
 
2.0 
Study Intervention/Investigational Agent 
2.1 If the research involves drugs or device, describe your plans to store, 
handle, and administer those drugs or devices so that they will be 
used only on subjects and be used only by authorized investigators. 
• 
If the control of the drugs or devices used in this protocol will 
be accomplished by following an established, approved 
organizational SOP (e.g., Research Pharmacy SOP for the 
Control of Investigational Drugs, etc.), please reference that 
SOP in this section. 
Response: The treatment provided to subjects is part of their routine 
clinical care as determined by their neurologist and the patients 
themselves. This project will not administer any drugs directly. The PET 
radiotracer will be produced directly on the morning before the scanning 
by the Canadian Molecular Probe Consortium (“CanProbe”) in Toronto
and transported to Buffalo. The contrast will be used during the PET scan


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 8 of 23 
IRB Version: 1/23/19 
at the Center for Biomedical Imaging in accordance with EH&S Radiation 
Safety Program.  The Ferumoxytol needed for research MRI scan will be 
kept in a locked cabinet in MRI suite available only to the investigators in 
the study. 
Healthy controls will not be given a contrast agent during collection of the 
MRI scan.  
 
2.2 If the drug is investigational (has an IND) or the device has an IDE 
or a claim of abbreviated IDE (non-significant risk device), include 
the following information: 
• 
Identify the holder of the IND/IDE/Abbreviated IDE. 
• 
Explain procedures followed to comply with sponsor 
requirements for FDA regulated research for the following: 
 
Applicable to: 
FDA Regulation 
IND Studies 
IDE studies 
Abbreviated 
IDE studies 
21 CFR 11 
X 
X 
 
21 CFR 54 
X 
X 
 
21 CFR 210 
X 
 
 
21 CFR 211 
X 
 
 
21 CFR 312 
X 
 
 
21 CFR 812 
 
X 
X 
21 CFR 820 
 
X 
 
Response: IND application is approved for 18F-PBR06. The IND approval 
by FDA is under the code “IND 156679”. The approval letter is included 
in the IRB submission. 
 
3.0 
Inclusion and Exclusion Criteria* 
3.1 Describe any inclusion or exclusion criteria that will differ for your 
local site compared to the sponsor’s protocol. For example, if the
sponsor’s protocol allows the enrollment of children but your site
will not enroll children, indicate that here.  
Response: This is a 1 site study (BNAC). Inclusion/exclusion criteria will 
be standard across any MS subjects to be enrolled. 15-age-matched 
healthy controls (10 females and 5 males aged between 18-65 years) will 
be enrolled. 
 
4.0 
Withdrawal of Subjects* 
4.1 Describe procedures that will be followed locally, if different than 
the sponsor’s protocol, when subjects withdraw from the research.


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 9 of 23 
IRB Version: 1/23/19 
Response: Any premature withdrawal from the study will be recorded in the 
appropriate CRF. The person will be off study (no future assessments) and 
continue with standard of care as prescribed by his/her neurologist. If the subject 
discontinues the medication for medical reasons, every attempt will be made to 
complete the End of Treatment (EoT) testing schedule. The healthy control cohort 
is not being treated for any pathology related to a neurological disease. 
 
5.0 
Vulnerable Populations* 
5.1 If the research involves individuals who are vulnerable to coercion 
or undue influence, describe additional safeguards included to 
protect their rights and welfare. 
• 
If the research involves pregnant women, review 
“CHECKLIST: Pregnant Women (HRP-412)” to ensure that
you have provided sufficient information. 
• 
If the research involves neonates of uncertain viability or non-
viable neonates, review “CHECKLIST: Neonates (HRP-413)”
or “HRP-414 – CHECKLIST: Neonates of Uncertain Viability 
(HRP-414)” to ensure that you have provided sufficient
information. 
• 
If the research involves prisoners, review “CHECKLIST:
Prisoners (HRP-415)” to ensure that you have provided
sufficient information. 
• 
If the research involves persons who have not attained the 
legal age for consent to treatments or procedures involved in 
the research (“children”), review the “CHECKLIST: Children
(HRP-416)” to ensure that you have provided sufficient 
information. 
• 
If the research involves cognitively impaired adults, review 
“CHECKLIST: Cognitively Impaired Adults (HRP-417)” to
ensure that you have provided sufficient information. 
• 
Consider if other specifically targeted populations such as 
students, employees of a specific firm or 
educationally/economically disadvantaged persons are 
vulnerable to coercion or undue influence.  The checklists 
listed above for other populations should be used as a guide to 
ensure that you have provided sufficient information.  
Response: Not applicable 
 
6.0 
Sharing of Results with Subjects* 
6.1 Describe whether or not results (study results or individual subject 
results, such as results of investigational diagnostic tests, genetic 
tests, or incidental findings) will be shared with subjects or others 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 10 of 23 
IRB Version: 1/23/19 
(e.g., the subject’s primary care physicians) and if so, describe how
it will be shared. 
Response: In the event that an incidental finding is discovered on the MRI 
images, the individual’s neurologist or primary care physician will be 
notified.  
 
7.0 
Setting 
7.1 Describe the local sites or locations where your research team will 
conduct the research.  
Response: For all participants, the MRI will take place at Buffalo General 
Hospital.  The PET exam will take place at the CBI, located on the CTRC, 
7th Floor or at Great Lakes Medical Imaging (GLMi) (199 Park Club 
Lane, Suite 300, Williamsville).  
For BNAC participants, clinical visits will take place at UBMD 
Neurology, located in the Conventus building at 1001 Main Street on the 
4th floor.    
 
 
7.2 Identify where your research team will identify and recruit potential 
subjects. 
Response: MS subjects were referred by their neurologist. Healthy 
controls subjects will be recruited locally.  
 
 
7.3 Identify where research procedures will be performed. 
Response:  
For all participants, the MRI will take place at Buffalo General Hospital.  
The PET exam will take place at the CBI, located on the CTRC, 7th Floor 
or at Great Lakes Medical Imaging (GLMi).  
For BNAC participants, clinical visits will take place at UBMD 
Neurology, located in the Conventus building at 1001 Main Street on the 
4th floor.  For MS subjects, the clinical visit, demographic and MRI screen 
questionnaires will be administered at Buffalo General Hospital. 
 
7.4 Describe the composition and involvement of any community 
advisory board. 
Response: Not applicable.


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 11 of 23 
IRB Version: 1/23/19 
 
7.5 For research conducted outside of the organization and its affiliates 
describe: 
• Site-specific regulations or customs affecting the research for 
research outside the organization. 
• Local scientific and ethical review structure outside the 
organization. 
Response: Not applicable. 
 
8.0 
Resources Available 
8.1 Describe the qualifications (e.g., training, experience, oversight) of 
you and your staff as required to perform their role. When 
applicable describe their knowledge of the local study sites, culture, 
and society. Provide enough information to convince the IRB that 
you have qualified staff for the proposed research. If you specify a 
person by name, a change to that person will require prior approval 
by the IRB. If you specify people by role (e.g., coordinator, research 
assistant, co-investigator, or pharmacist), a change to that person 
will not typically require prior approval by the IRB, provided that 
person meets the qualifications described to fulfill their roles. 
Response: The clinicians are board certified neurologists and are 
considered experts in their field. 
Clinical research unit (CRU) staff and Dent study team members– 
including project coordinators, clinical trial managers, and quality review 
associates – are certified in CITI and GCP.  Staff within this unit are 
trained on all relevant SOPs and have access to all study-related 
documentation (e.g., protocol, scope of work, etc.).  Additionally, CRU 
staff attend weekly teleconferences with the sponsor to ensure the staff is 
up-to-date on all study procedures and potential protocol deviations. 
MRI analysis unit (MRIAU) staff – including analysts, physicists, and 
technical support – are certified in CITI and GCP.  Staff within this unit 
are trained in all computer programs being utilized (JIM, Linux, etc.) and 
have an average of 7 years’ experience in the field of MS brain analyses.
Staff within this unit are trained on all relevant SOPs and have access to 
all study-related documentation (e.g., protocol, scope of work, etc.) and 
attend calibration meetings to ensure consistency among analysts. 
PET and MRI staff are highly trained and certified to conduct these scans.  
 
 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 12 of 23 
IRB Version: 1/23/19 
Describe other resources available to conduct the research: For example, 
as appropriate: 
8.2 Justify the feasibility of recruiting the required number of suitable 
subjects within the agreed recruitment period. For example, how 
many potential subjects do you have access to? What percentage of 
those potential subjects do you need to recruit? 
Response: We plan to enroll 60 patients over an 18-month period. We 
believe this is quite feasible. Approximately 10 patients are prescribed 
Ocrevus and Mayzent in a month. (5 each) – no longer applicable 
 We also plan to enroll 15 healthy controls who are age and gender 
matched.  
 
 
8.3 Describe the time that you will devote to conducting and completing 
the research. 
Response: 60 months 
 
8.4 Describe your facilities. 
Response: BNAC is an MRI reading center located within Buffalo General 
Hospital; we are protected by both the hospital firewall and internal 
firewalls to prevent breach of data. DENT Neurologic Institute is the 
largest out-patient neurology practice in the United States. GLMI currently 
provides the radiology services for 6 hospitals and at 5 outpatient locations 
in and around Buffalo NY. 
 
 
8.5 Describe the availability of medical or psychological resources that 
subjects might need as a result of an anticipated consequences of the 
human research. 
Response: Subjects will always have access to their neurologists or 
primary care physician. 
 
8.6 Describe your process to ensure that all persons assisting with the 
research are adequately informed about the protocol, the research 
procedures, and their duties and functions. 
Response: The protocol will be shared with all personnel involved in 
recruiting, testing, and receiving, analyzing, and reporting on MRIs.  
BNAC has staff meetings to inform the appropriate personnel at the


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 13 of 23 
IRB Version: 1/23/19 
beginning of each study and as necessary throughout the duration of the 
research.  
 
 
9.0 
Prior Approvals 
9.1 Describe any approvals that will be obtained prior to commencing 
the research. (E.g., school, external site. funding agency, laboratory, 
radiation safety, or biosafety approval.) 
Response: None. 
 
10.0 Local Recruitment Methods 
 
This section is for recruitment methods under the control of the local site and not 
central recruitment managed by the sponsor.   
10.1 Describe when, where, and how potential subjects will be recruited. 
Response: Subjects who were eligible to be prescribed Mayzent or 
Ocrevus by their neurologist while attending a clinical visit at UBMD 
Neurology at Conventus or the Dent Neurologic Institute. Healthy control 
subject will be recruited locally. 
 
 
10.2 Describe the source of subjects. 
Response: Patients who visit UBMD Neurology or Dent for management 
and treatment of SPMS. Healthy control subjects will be from other 
studies which they participated in and consented to be contacted for 
participation in future studies.  
 
10.3 Describe the methods that will be used to identify potential subjects. 
Response: Neurologists will assess their patients’ eligibility to be 
prescribed either Mayzent or Ocrevus. All patients must be screened, per 
clinical protocols, to determine the safety of taking the prescribed 
medicine. No longer applicable 
Healthy control subjects will be from other studies which they participated 
in and consented to be contacted for participation in future studies. 
 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 14 of 23 
IRB Version: 1/23/19 
10.4 Describe materials that will be used to recruit subjects. (Attach 
copies of these documents with the application. For advertisements, 
attach the final copy of printed advertisements. When advertisements 
are taped for broadcast, attach the final audio/video tape. You may 
submit the wording of the advertisement prior to taping to preclude 
re-taping because of inappropriate wording, provided the IRB 
reviews the final audio/video tape.) 
Response: No materials; neurologist referrals.  
Healthy control subjects will be from other studies which they participated 
in and consented to be contacted for participation in future studies. 
 
10.5 Describe the amount and timing of any payments to subjects. 
Response: Subjects will be paid by check for taking part in this study at 
each time point as it follows: 
• If they complete the clinical visits, they will be paid $50 
• If they complete a PET scan, they will be paid $100 per PET scan 
• If they complete planned MRI scan over day one, they will be paid $50 
and if they complete both MRIs over 2 days, they will be paid $100 
• Healthy control subjects will be paid $250 after completion of the PET 
and MRI scans. 
 
The total amount MS subjects may receive for taking part at every time 
point visit is $250. If the subject has to stop any procedure of the study 
visit early for any purpose, he/she will still receive compensation for 
his/her time, as above. 
If MS subjects participate through all procedures in all five visits, they 
will be compensated in total of $1250. 
 
• Healthy control subjects will be paid $250 after completion of the PET 
and MRI scans. 
 
11.0 Local Number of Subjects 
11.1 Indicate the total number of subjects to be accrued locally. 
Response: 60 MS (no longer applicable); 15 HCs 
 
11.2 If applicable, distinguish between the number of subjects who are 
expected to be enrolled and screened, and the number of subjects 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 15 of 23 
IRB Version: 1/23/19 
needed to complete the research procedures (i.e., numbers of 
subjects excluding screen failures.) 
• Response: We estimate that 90 MS patients will need to be screened in 
order to achieve our enrollment goal of 60. No longer applicable 
• Healthy control subjects will be from other studies which they participated 
in and consented to be contacted for participation in future studies. 
 
 
 
12.0 Data Management and Confidentiality 
Describe the local procedures for maintenance of confidentiality. 
12.1 Where and how data or specimens will be stored locally? 
Response: Electronic data will be stored on password-protected, dual-
firewall encrypted machines in BNAC.  Paper documentation is stored in 
locked cabinets in a locked room in the BNAC lab.  
12.2 How long the data or specimens will be stored locally? 
Response: MRIAU will have access to MRIs and ROI files.  CRU will 
have access to paper and electronic clinical, cognitive and administrative 
documentation.  The database management unit (DMU) will have access 
to the compiled data from our online repository. 
 
12.3 Who will have access to the data or specimens locally? 
Response: MRIAU will have access to MRIs and ROI files.  CRU will 
have access to paper and electronic clinical, cognitive and administrative 
documentation.  The database management unit (DMU) will have access 
to the compiled data from our online repository. 
 
12.4 Who is responsible for receipt or transmission of the data or 
specimens locally? 
Response: UBMD and Dent neurologists are responsible for conducting 
and documenting the clinical visit. CRU is responsible for collecting the 
clinical data and associated testing data and receiving MRIs. The DMU is 
responsible for data entry and working with the PI on study-related 
database matters. 
 
 
12.5 How data and specimens will be transported locally?


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 16 of 23 
IRB Version: 1/23/19 
Response: Data is not transported to any external collaborators. 
 
13.0 Provisions to Protect the Privacy Interests of Subjects 
13.1 Describe the steps that will be taken to protect subjects’ privacy
interests. “Privacy interest” refers to a person’s desire to place
limits on whom they interact or whom they provide personal 
information. 
Response: Potential participants will meet with a full-time study 
coordinator in a private room where no one can overhear.  The potential 
participants are provided all information regarding the full testing battery, 
length of participation, and reimbursement and reminded that their 
participation is entirely voluntary.  At this time, participants are also able 
to ask additional questions regarding their participation.   
 
13.2 Describe what steps you will take to make the subjects feel at ease 
with the research situation in terms of the questions being asked and 
the procedures being performed. “At ease” does not refer to
physical discomfort, but the sense of intrusiveness a subject might 
experience in response to questions, examinations, and procedures. 
Response: MS patients are very familiar with the tests being performed as 
part of this study. They are able to ask questions at any time. They can 
decline to answer any questions if they find them intrusive or 
uncomfortable. MRI, PET and lab assessments are only performed by 
licensed personnel. Tests are conducted in private settings.   
Healthy control subjects will only undergo 1 MRI and 1 PET scan.  
 
13.3 Indicate how the research team is permitted to access any sources of 
information about the subjects. 
Response: Specifically, data is accessible only by those who have been 
assigned to the study and have the requisite training and experience. Each 
study personnel have their own logon ids and passwords to access the 
secure network drive at BNAC. Dent and Great Lakes Medical Imaging 
will not be housing any study related data. After collection, all study 
materials are given to BNAC.  
 
14.0 Compensation for Research-Related Injury 
14.1 If the research involves more than Minimal Risk to subjects, describe 
the available compensation in the event of research related injury. 
Response:  


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 17 of 23 
IRB Version: 1/23/19 
Participants will receive medical treatment if they are injured or become 
ill as a result of this study. The doctor will explain the treatment options to 
them and tell them where they can get treatment. 
The University at Buffalo and the Buffalo Neuroimaging Analysis Center 
(BNAC) makes no commitment to provide free medical care or payment 
for any unfavorable outcomes that result from their participation in this 
research. Medical services will be billed at the usual charge and will be the 
participant’s responsibility or that of their third-party payer but the 
participants are not precluded from seeking to collect compensation for 
injury related to malpractice, fault, or blame on the part of those involved 
in the research including (BNAC) and the University at Buffalo.”  
 
 
 
14.2 Provide a copy of contract language, if any, relevant to 
compensation for research-related injury. 
Response: Not applicable. 
 
15.0 Economic Burden to Subjects 
15.1 Describe any costs that subjects may be responsible for because of 
participation in the research, e.g., fuel, parking, childcare. 
Response: The subject does not have to pay for any of the procedures 
involved in this study. 
 
16.0 Consent Process 
16.1 Indicate whether you will be obtaining consent. 
Response: Yes. 
 
16.2 Describe where the consent process take place. 
Response: Consenting will take place in a private room within BNAC 
UBMD Neurology, or Dent (no longer applicable). 
 
 
16.3 Describe any waiting period available between informing the 
prospective subject and obtaining the consent. 
Response: When subjects are approached about participation in this study
they can either choose to be consented and start the screening process at 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 18 of 23 
IRB Version: 1/23/19 
that time, or they can contact a study coordinator at a later date of their 
choosing.   
 
 
16.4 Describe any process to ensure ongoing consent. 
Response: If there are any changes to the study procedures (see study 
closure letter for patients), subjects will be informed (possibly even asked 
to sign a new consent based on the change). The subjects are reminded 
that participation is voluntary and they are free to stop participating at any 
time without penalty or change to their clinical care.  
 
16.5 Describe whether you will be following “SOP: Informed Consent 
Process for Research (HRP-090).” Pay particular attention to 
Sections 5.4-5.9. If not, or if there are any exceptions or additional 
details to what is covered in the SOP, describe: 
• 
The role of the individuals listed in the application as being 
involved in the consent process. 
• 
The time that will be devoted to the consent discussion. 
• 
Steps that will be taken to minimize the possibility of coercion 
or undue influence. 
• 
Steps that will be taken to ensure the subjects’ understanding. 
Response: ☒ We have reviewed and will be following “SOP: Informed
Consent Process for Research (HRP-090).” 
 
 
Non-English Speaking Subjects  
16.6 Indicate what language(s) other than English are likely to be 
spoken/understood by your prospective study population or their 
legally authorized representatives. 
Response: Non-English speaking subjects will not be enrolled. The study 
is observational and does not offer any direct benefit. 
 
16.7 
Indicate whether you will include non-English speaking individuals in 
your study.  Provide justification if you will exclude non-English speaking 
individuals.  
In order to meet one of the primary ethical principles of equitable selection 
of subjects, non-English speaking individuals may not be routinely excluded 
from research as a matter of convenience.


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 19 of 23 
IRB Version: 1/23/19 
In cases where the research is of therapeutic intent or is designed to 
investigate areas that would necessarily require certain populations who 
may not speak English, the researcher is required to make efforts to recruit 
and include non-English speaking individuals.  However, there are studies 
in which it would be reasonable to limit subjects to those who speak 
English.  Some examples include pilot studies, small unfunded studies with 
validated instruments not available in other languages, studies with 
numerous questionnaires, and some non-therapeutic studies which offer no 
direct benefit. 
Response: This study has many questionnaires, all written in English. It is vital 
that study subjects are able to communicate with their neurologist regarding their 
medications and clinical care and that they are able to understand instructions 
when under-going MRI and PET scanning.  
 
16.8 If subjects who do not speak English will be enrolled, describe the 
process to ensure that the oral and written information provided to 
those subjects will be in that language, how you will ensure that 
subjects are provided with a sufficient period of time to consider 
taking part in the research study, and any process to ensure ongoing 
consent. Indicate the language that will be used by those obtaining 
consent. 
NOTE: Guidance is provided on “SOP: Informed Consent Process for Research 
(HRP-090).” 
 
 
Response: Non-English speaking subjects will not be enrolled. 
 
 
Waiver or Alteration of Consent Process (consent will not be obtained, 
required information will not be disclosed, or the research involves 
deception) 
16.9 Review the “CHECKLIST: Waiver or Alteration of Consent Process 
(HRP-410)” to ensure you have provided sufficient information for
the IRB to make these determinations. Provide any additional 
information necessary here: 
Response: We are not requesting a waiver of the consent process. 
 
16.10If the research involves a waiver the consent process for planned 
emergency research, please review the “CHECKLIST: Waiver of 
Consent for Emergency Research (HRP-419)” to ensure you have


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 20 of 23 
IRB Version: 1/23/19 
provided sufficient information for the IRB to make these 
determinations. Provide any additional information necessary here: 
Response: Not applicable.  
 
Subjects who are not yet adults (infants, children, teenagers) 
16.11Describe the criteria that will be used to determine whether a 
prospective subject has not attained the legal age for consent to 
treatments or procedures involved in the research under the 
applicable law of the jurisdiction in which the research will be 
conducted. (E.g., individuals under the age of 18 years.) For 
research conducted in NY state, review “SOP: Legally Authorized 
Representatives, Children, and Guardians (HRP-013)” to be aware
of which individuals in the state meet the definition of “children.” 
Response: Only adults aged 18-60 will be enrolled in this study. 
 
 
16.12For research conducted outside of NY state, provide information that 
describes which persons have not attained the legal age for consent 
to treatments or procedures involved the research, under the 
applicable law of the jurisdiction in which research will be 
conducted. One method of obtaining this information is to have a 
legal counsel or authority review your protocol along the definition 
of “children” in “SOP: Legally Authorized Representatives, 
Children, and Guardians (HRP-013).” 
Response: Research is only being conducted in NYS. 
 
 
16.13Describe whether parental permission will be obtained from: 
• 
Both parents unless one parent is deceased, unknown, 
incompetent, or not reasonably available, or when only one 
parent has legal responsibility for the care and custody of the 
child. 
• 
One parent even if the other parent is alive, known, competent, 
reasonably available, and shares legal responsibility for the 
care and custody of the child. 
Response: Not applicable. 
 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 21 of 23 
IRB Version: 1/23/19 
16.14Describe whether permission will be obtained from individuals other 
than parents, and if so, who will be allowed to provide permission. 
Describe the process used to determine these individuals’ authority
to consent to each child’s general medical care. 
Response: Not applicable.  
 
16.15Indicate whether assent will be obtained from all, some, or none of 
the children. If assent will be obtained from some children, indicate 
which children will be required to assent. 
Response: Not applicable.  
 
16.16When assent of children is obtained describe whether and how it will 
be documented. 
Response: Not applicable.  
 
Cognitively Impaired Adults 
16.17Describe the process to determine whether an individual is capable 
of consent. The IRB sometimes allows the person obtaining assent to 
document assent on the consent document and does not 
automatically require assent documents to be used. 
Response: We will not be enrolling cognitively impaired adults. 
 
Adults Unable to Consent 
When a person is not capable of consent due to cognitive impairment or 
decisional incapacity, a legally authorized representative must be used to 
provide consent and, where possible, assent of the individual should also 
be solicited. 
16.18List the individuals from whom permission will be obtained in order 
of priority. (e.g., durable power of attorney for health care, court 
appointed guardian for health care decisions, spouse, and adult 
child.)  For research conducted in NY state, review “SOP: Legally 
Authorized Representatives, Children, and Guardians (HRP-013)”
to be aware of which individuals in the state meet the definition of 
“legally authorized representative.”  The list in the consent template 
signature section corresponds to the priority list for New York State.   
Response: Only persons who are willing and able to provide informed 
consent will be enrolled in this study.  


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 22 of 23 
IRB Version: 1/23/19 
 
16.19For research conducted outside of New York state, provide 
information that describes which individuals are authorized under 
applicable law to consent on behalf of a prospective subject to their 
participation in the procedure(s) involved in this research. One 
method of obtaining this information is to have a legal counsel or 
authority review your protocol along the definition of “legally
authorized representative” in “SOP: Legally Authorized 
Representatives, Children, and Guardians (HRP-013).” 
Response: This research will only take place in NYS. 
 
16.20Describe the process for assent of the subjects. Indicate whether: 
• 
Assent will be required of all, some, or none of the subjects. If 
some, indicate which subjects will be required to assent and 
which will not. 
• 
If assent will not be obtained from some or all subjects, an 
explanation of why not. 
• 
Describe whether assent of the subjects will be documented 
and the process to document assent. The IRB allows the person 
obtaining assent to document assent on the consent document 
and does not routinely require assent documents and does not 
routinely require subjects to sign assent documents. 
Response: Not applicable. 
 
17.0 Process to Document Consent in Writing 
17.1 Describe whether you will be following “SOP: Written 
Documentation of Consent (HRP-091).” If not, describe whether and
how consent of the subject will be obtained including whether or not 
it will be documented in writing. 
Response: We will be following HRP-091. 
 
18.0 Data and Specimen Banking* 
18.1 The sponsor’s protocol may require banking data or specimens for
future use and both storage and use will be determined by the 
sponsor. If additional data or specimens will be banked locally for 
future use, describe where the specimens will be stored, how long 
they will be stored, how the specimens will be accessed, and who 
will have access to the specimens. 


PROTOCOL TITLE: Open-label, single-blinded, observational, prospective, 36-month, 
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on
microglia in patients with secondary progressive forms of multiple sclerosis  
 
Page 23 of 23 
IRB Version: 1/23/19 
Response: Data will be kept on site for the duration of the study and 
archived thereafter for the requisite 7 years.  Hard copies will be locked in 
a separate, secure filing room open only to project coordinators and 
clinical trial managers.  Electronic data will be kept on a password- and 
dual firewall-protected server available only to MRI analysts, physicists, 
technical-, and clinical-support staff. 
 
 
18.2 List the data to be stored or associated with each specimen banked 
locally. 
Response: MRI data with superimposed region of interest (ROI) files will 
be saved on the server. CRFs, clinical data and informed consent will all 
be kept and archived in BNAC. Data will be centrally managed by BNAC 
on a secure network. The network is password protected and can be 
accessed only by personnel as directed by the BNAC Director. Clinical 
data is stored in BNAC in coded charts that do not contain names, only 
study identifiers. All CRFs, MRI data, informed consent and other study 
data will be kept and archived in BNAC. The data will be quality 
controlled by BNAC and Jacobs MS Center staff. Information related to 
data will be treated in strict confidence to the extent provided by law.   
 
18.3 Describe the procedures to release locally banked data or 
specimens, including: the process to request a release, approvals 
required for release, who can obtain data or specimens, and the data 
to be provided with specimens. 
Response: A password-protected database will be sent to the sponsor at 
his/her written request.  No data will otherwise be shared with any 
organization or entity. 
 
 
 


Statistical Analysis Plan 
“Open-label, single-blinded, comparative, prospective, 36-month, longitudinal, controlled 
study to assess the efficacy of siponimod (Mayzent®) on microglia in patients with active 
secondary progressive forms of multiple sclerosis”  
2023-09-15 
 
All statistical analyses were performed using SPSS version 28.0 (IBM, Armonk, NY, USA). The 
data distribution was determined using visual inspection of the histograms and Q-Q plots.  
Categorical data was compared using chi-square test, parametric numerical data was 
compared using Student’s t-test and non-parametric data using Mann Whitney U test. The 
comparisons between the groups were further adjusted for demographic and genetic differences 
using analysis of covariance (ANCOVA) and adjusted estimated means were shown as mean 
(standard error).  
Due to the small sample size and non-parametric nature of the data, the correlations were 
performed using non-parametric Spearman’s test. Pair-wise comparisons within the subjects 
were also performed. P-values lower than 0.05 were considered statistically significant. Due to 
the exploratory nature of the study, corrections for multiple comparisons were omitted. The data 
was additionally visualized using box and scatter plots. 
MRI Analysis 
Lesion activity: 
The CE gadolinium and USPIO lesion number and lesion volume (LV) were measured on T1 
post-contrast images, respectively, using a semi-automated edge detection 
contouring/thresholding technique previously described. Unenhanced T1 images were always 
used for comparison, and USPIO and gadolinium CE lesions were judged together as they 
would theoretically be in clinical situations. The cumulative number of CE gadolinium and 
USPIO lesions were obtained by summing the total number of these lesions between baseline 
to 6, 6 to 12, 12 to 24 months and 24 to 36 months. 
The T2 new/enlarging lesions were assessed on FLAIR sequence. Using FMRIB's 
FLIRT, all follow-up FLAIR and T1-SE post-contrast images for a given subject were co-
registered to its baseline FLAIR image using a 6 degrees-of-freedom rigid-body model. All 
subsequent lesion analyses were done using the co-registered images. For each time point, T2 
lesion activity analysis was performed via the aid of a "subtraction image." Briefly, the image 
from the previous time point was subtracted from the corresponding current image. The result 
was then be smoothed with a Gaussian kernel of 0.5 mm. Cross-sectional regions of interest 
was overlaid on the subtraction image to facilitate the identification of new and enlarging T2 
lesions. T2 and T1-LCs was calculated using JIM software (version 6.0, Xinapse Systems, 
Northants, UK, http://www.xinapse.com). 
Brain volume analysis: 
Segmentation of deep GM structures for volumetric and QSM analysis were done using both a 
semi-automated edge-contouring and FMRIB's integrated registration and segmentation tool 
(FIRST) on 3D T1-WI. Absolute tissue volumes for the thalamus and total subcortical deep GM 
at each time point were estimated from inpainted 3D T1-WI images with FMRIB's Integrated 


Registration and Segmentation Tool, a model-based segmentation/registration tool. Normalized 
volumes were obtained by multiplying the estimated volumes from this tool by the volumetric 
scaling factor from SIENAX and percentage volume changes were obtained between different 
time points. Percent thalamus volume change (PTVC) was calculated. 
For baseline analyses, FMRIB’s SIENAX software was used (version 2.6) with inpainted 
3D T1-WI. Normalized volumes were measured. 
To quantify longitudinal percentage volume changes, we used a modified hybrid of 
FMRIB's SIENA and SIENAX methods. We used a brain- and skull-constrained co-registration 
technique to place both baseline and follow-up images into a joint space halfway between the 
two at all time points in the study. Next, we combined baseline and follow-up intracranial volume 
masks via union and valid voxel masks via intersection, ensuring that the same imaging volume 
was analyzed at both time points. Finally, we segmented the resulting images with a modified 
longitudinal version of FMRIB's Automated Segmentation Tool that uses a 4-dimensional joint 
hidden random Markov field to prevent misclassification between time points when longitudinal 
intensity changes are lacking (or minimal). Total tissue volume was calculated for both baseline 
and follow-up for each tissue compartment from partial volume maps and percentage volume 
change was derived directly from the images. Percentage brain volume change (PBVC) and 
percentage cortical volume change (PCVC) was calculated.  
QSM analyses: 
QSM images were reconstructed as previously described. Magnetic susceptibility was 
referenced (0 ppb) to the average susceptibility of the brain, under the assumption that a larger 
reference region would reduce additional inter-subject variability, compared to a smaller 
reference region. In-house developed algorithms for QSM processing, written in MATLAB 
(2013b, The MathWorks, Natick, MA) was used. 
PET analysis: 
Prior to regional analysis, subject-specific SUV maps were created. First, list-mode data was 
reconstructed into 5-minute frames and then aligned in order to correct for patient motion (see 
Figure 6 for further details). Next, aligned, decay-corrected activity maps were combined and then 
converted to voxel-wise standardized uptake value (SUV) maps (Figure 7) based on injected dose 
(ID) and body weight (BW) at the time of injection, using the formula SUV=Cimg/(ID/BW). To 
facilitate subsequent regional analysis, SUV maps were fused with MRI using the CT scan as an 
anatomical proxy. 
 
For lesional and non-lesional NAWM and NAGM, and the peri-plaque area of chronic lesions in 
the brain analyses, the derived regions and/or expert-traced regions of interest (ROIs) from the 
fused MRI were applied to the PET scans to determine lesional and non-lesional 18F-PBR06 
binding. To correct for individual variation in tracer kinetics, SUV measures were referenced to 
the mean SUV of the cerebellum to produce relative SUVR measures for each relevant region 
of interest. Additionally, to correct for partial voluming of the larger PET voxels compared to 
MRI, region-based voxel-wise (RBV) correction combined with the reblurred Van-Cittert (RVC) 
was employed using PETPVC. 
 
 


 


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 1 of 12
University at Buffalo Institutional Review Board (UBIRB)
Office of Research Compliance | Clinical and Translational Research Center Room 5018
875 Ellicott St. | Buffalo, NY 14203
UB Federalwide Assurance ID#: FWA00008824
Adult Consent to Participate in a Research Study as a Participant with Multiple
Sclerosis for DENT participants.
Title of research study: Open-label, single-blinded, observational, prospective, 36-month,
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on microglia in
patients with secondary progressive forms of multiple sclerosis
Version Date: 28Feb22
Investigator: Robert Zivadinov, MD, PhD
Key Information: The following is a short summary of this study to help you decide whether or
not to be a part of this study. More detailed information is listed later on in this form.
Why am I being invited to take part in a research study?
You are being invited to take part in a research study because you have been diagnosed with a
secondary progressive form of multiple sclerosis and will be starting treatment with either Mayzent or
Ocrevus, as part of your clinical routine treatment.
What should I know about a research study?

Someone will explain this research study to you.

Whether or not you take part is up to you.

You can choose not to take part.

You can agree to take part and later change your mind.

Your decision will not be held against you.

You can ask all the questions you want before you decide.
Why is this research being done?
The purpose of this research is to examine the association between the development of microglia-
related pathology using positron emission tomography (PET) and magnetic resonance imaging (MRI)
in secondary progressive MS patients being treated with Mayzent or Ocrevus. Microglia is a type of
cell found in the brain and spinal cord that is involved in the pathogenesis of multiple sclerosis (MS).
Greater activation of these cells is related to development of secondary progressive MS, but it is
unknown whether there is an effect of currently available MS treatments on these types of cells.
Therefore, this research will use advanced imaging techniques to answer this important question using
two commonly available, FDA approved, MS treatments.
How long will the research last and what will I need to do?
We expect that you will be in this research study for 5.5 hours at every time point, 3 years. There are 5
testing time points (baseline, 6 months, 12 months, 24 months and 36 months).
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 2 of 12
Each testing point, you will be asked to have two MRI exams, a PET scan, and an Optical Coherence
Tomography scan (OCT; eye exam). You will also be asked to complete a 25-foot walk, attend clinical
visits with your neurologist and to complete questionnaires to ensure it is safe for you to have an MRI.
An additional 4 questionnaires will evaluate your memory and mental processing. You will also have
blood taken for laboratory examinations.
More detailed information about the study procedures can be found under “What happens if I say yes,
I want to be in this research?”
Is there any way being in this study could be bad for me?
Pregnant women will not be eligible to participate in this study.
During the MRI exam, you will be lying on your back. You may experience discomfort from lying
still during the exam, or mild claustrophobia. To reduce discomfort, a cushion will be placed under
your knees. Your head will be resting on a device called a head coil, which is necessary to collect the
images. When images are being acquired, the MRI scanner produces continuous loud noise, which
sounds like rapid hammering. You will be given ear plugs to help block out the sound of the MRI
scanner. You may be offered headphones to listen to music during your scan. There is a microphone
and a speaker in the MRI scanner, so you will be able to talk to the MRI technologist between scans.
You will also be given a ‘call ball’ to hold in your hand during the exam that you can use if you
urgently need to stop the exam.
During the PET scan, you will be exposed to radiation and during MRI of injection of gadolinium and
Ferumoxytol. Please note that this radiation is not necessary for your medical care and is for research
purposes only.
During the insertion of the IVs (MRI and PET) and blood draw you may experience a little pain at the
site, some bruising and redness. Allergic reactions with the MRI contrast agent are very rare. However,
there could be some itchy, redness at the injection site.
There are no known risks associated with the eye exam, clinical testing, physical, neurological, or
cognitive assessments.
More detailed information about the risks of this study can be found under “Is there any way being in
this study could be bad for me? (Detailed Risks)”
Will being in this study help me in any way?
There are no benefits to you from your taking part in this research. We cannot promise any benefits to
others from your taking part in this research. However, possible benefits to others include better
understanding of the interaction between cell components and other biological and clinical factors.
What happens if I do not want to be in this research?
Participation in research is completely voluntary. You may choose not to enroll in this study. Your
alternative to participating in this research study is to not participate.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 3 of 12
Detailed Information: The following is more detailed information about this study in
addition to the information listed above.
Who can I talk to?
If you have questions, concerns, or complaints, or think the research has hurt you, talk to the research
team at rzivadinov@bnac.net (716-859-7040) or welmalik@dentinstitute.com (716-250-2000). You
may also contact the research participant advocate at 716-888-4845 or researchadvocate@buffalo.edu.
This research has been reviewed and approved by an Institutional Review Board (“IRB”). You may
talk to them at (716) 888-4888 or email ub-irb@buffalo.edu
if:

You have questions about your rights as a participant in this research

Your questions, concerns, or complaints are not being answered by the research team.

You cannot reach the research team.

You want to talk to someone besides the research team.

You want to get information or provide input about this research.
How many people will be studied?
We expect to recruit 60 people in this research study.
What happens if I say yes, I want to be in this research?
If you take part in this research, you will be asked to have two MRI exams, a PET scan, Optical
Coherence Tomography (OCT; eye exam), and have physical and cognitive assessments. These tests
are being conducted per the research protocol. Testing time points are 0 (baseline), and months 6, 12,
24, 36. For all participants, the MRI will take place at Buffalo General Hospital. The PET exam will
take place at the Center for Biomedical Imaging, located on the Clinical Translational Research Center,
875 Ellicott St., Buffalo, 7th Floor. Clinical visits, OCT (eye exam) and study questionnaires will be
administered at Dent.
Genotyping for the DNA polymorphism of the TSPO gene on chromosome 22q13.2 SNP:
All subjects will be genotyped for the DNA polymorphism of the TSPO gene on chromosome 22q13.2.
This test allows us to determine the eligibility of each subject to proceed in the study. The information
regarding these genes allows us to determine your ability to interface with the injected molecules. This
procedure allows comparing subjects despite their different genetic background.
MRI (total of 10 scans for entire study; 2 scans at each time point)
The MRI will happen at Buffalo General Hospital on the 1st floor. The MRI will take approximately
2.5 hours over 2 days. The first day, you will perform an MRI scan similar to the one you usually
obtain for the follow-up monitoring of your disease. Within the first approximately 45-50 minutes in
the scanner, you will have a clinical routine MRI scan with use of gadolinium contrast agent
administered through IV by a nurse. After the first 45-50 minutes of scanning with use of gadolinium
contrast agent, you will start the research portion of the MRI scan which will utilize another injection
of contrast agent known as Ferumoxytol. The injection will take about 15 minutes followed by 45
minutes of observational period. You will be observed for any signs or symptoms of an allergic
reaction or intolerance to the contrast agent. That will conclude the first day of MRI scanning. You
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 4 of 12
will have the opportunity to take a 15 minute break after first 50 minutes of clinical routine scanning
on the first day.
Because, it takes 24 hours for the Ferumoxytol contrast to become visible in the brain, in case of
microglia activity, you will need to come on the next day to obtain a second MRI scan. When you
come back the next day, you will be in the scanner only for approximately 15 minutes.
During the MRI procedure, you will be asked to lie on your back in the MRI machine. The MRI
machine is a small tunnel into which you will be inserted. You will lie on your back and cannot move
for the duration of testing. You will have a call button with which you can communicate with the
technician performing the test. The MRI can produce loud knocking sounds. You can use ear plugs to
reduce the noise if you wish.
PET (total of 5 visits for entire study)
The PET scanning is not performed in a clinical routine follow-up of MS patients. However, PET
imaging is utilized in MS patients for research purposes. Therefore, the use of PET in this study will be
done only for research purposes, to study microglia activation in the brain. During the research PET
procedure, you will lie down on a padded table with your head in a special rest position so that you can
stay still throughout the scan. You will then have an IV placed into your arm or hand in order to inject
a tracer agent or dye typically used in routine PET scanning. During this procedure you will have 2
blood draws (about 4 teaspoons).. The whole PET session will last approximately 90 min. After you
will be injected with the radiotracer, you will be observed for 45 min and then scanned for 45 minutes
(between 45 to 90 minutes after injection). Additional 15 min will be used for position/removal of the
patient in the injection room and PET/CT scanner. The scanner is very quiet. You can also listen to
music or sleep during the scan. You will be asked to drink plenty of water before and after the scan to
help flush the dye out of your system after scanning.
OCT (total of 5 visits for entire study)
This test will only take 5-10 minutes. We scan both of your eyes looking at the health of your eyes.
Low Contrast Letter Acuity (LCLA) has letters with varying sizes in different rows. You will be asked
to read those letters. This test helps to measure your visual functioning.
Both tests are used for clinical routine follow-up purposes.
Clinical Visit (total of 5 visits for entire study)
You will see your neurologist for your physical and neurological assessments. These visits are routine
in nature in that they should mimic your usual appointments that you have had with your neurologist in
the past.
Health Questionnaires
You will be asked questions about your health status, medication use, and MS symptoms. This
questionnaire is used for clinical routine follow-up purposes.
Health Screen Questionnaire
You will be asked questions about your overall health, education, and previous brain injuries. This
questionnaire will take roughly 10 minutes to complete. This questionnaire is used for clinical routine
follow-up purposes.
MRI Pre-Screen Questionnaire
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 5 of 12
You will be asked questions about certain types of medical procedures and implants that may make it
unsafe for you to complete an MRI. This questionnaire will take roughly 15 minutes to complete and
is used for clinical routine follow-up purposes.
Contrast Screen
You will be asked a few questions about medications and any history of diabetes or kidney disease.
Women of child bearing age will be asked about pregnancy.
Cognitive Questionnaires (no testing at the 6 month time point)
You will be asked to complete:
Symbol Digit Modalities Test (SDMT): This is a quick screen test for motor, visual and learning
problems.
California Verbal Memory Test – Second Edition (CVLT-II): This test measures verbal learning and
memory.
Brief Visuospatial Memory Test – Revised (BVMT-R): Tis test measures visuospacial learning and
memory abilities.
The Auditory Test of Processing Speed (ATOPS): is a novel test being developed and piloted by the
Benedict Lab to assess cognitive processing speed in individuals who may have severe motor or visual
impairments. Patients are read a series of numbers and asked to answer simply "Yes" or "No" as to
whether each number meets a pre-specified criteria.
At 12, 24, and 36 months we will ask you to complete a timed 25-feet walk (T25FW) test (testing
lower extremity function) and the Nine-Hole Peg test (9-HPT) (testing upper extremity function).
Trained technicians will administer these questionnaires which take roughly 60 minutes to complete.
These tests are used for clinical routine follow-up purposes.
A small amount of blood will be drawn (approximately 2 tablespoons). This will be used for research
purpose of investigating experimental biomarkers related to microglia activity in the blood.
What are my responsibilities if I take part in this research?
We ask that you are honest in your responses during testing throughout the study. If you are
uncomfortable with any question or procedure, you can stop and voluntarily stop participation with no
penalty nor any change to your routine clinical care.
Women of child-bearing potential should adhere to the contraception requirement for the duration of
the study. If there is any question that the patient will not reliably comply, they should not be entered
in the study.
What happens if I say yes, but I change my mind later?
You can leave the research at any time. It will not be held against you.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 6 of 12
Is there any way being in this study could be bad for me? (Detailed Risks)
During the MRI exam, you will be lying on your back. You may experience discomfort from lying
still during the exam, or mild claustrophobia. To reduce discomfort, a cushion will be placed under
your knees. Your head will be resting on a device called a head coil, which is necessary to collect the
images. When images are being acquired, the MRI scanner produces continuous loud noise, which
sounds like rapid hammering. You will be given ear plugs to help block out the sound of the MRI
scanner. You may be offered headphones to listen to music during your scan. There is a microphone
and a speaker in the MRI scanner, so you will be able to talk to the MRI technologist between scans.
You will also be given a ‘call ball’ to hold in your hand during the exam that you can use if you
urgently need to stop the exam. The MRI has a potential, during normal use to cause localized
warming of your skin and the underlying tissues. You should immediately inform us if you experience
discomfort due to warming and the procedure will be stopped.
The MRI scan uses a contrast agent called gadolinium to improve the image quality of the
MRI. You will receive an intravenous injection of a contrast dye compound that is routinely used
as part of standard MRI tests, but do have risks. During the placement of the IV, there may be
pain from the needle or you may experience mild dizziness. A bruise where the needle was
inserted could result after the IV is taken out. Gadolinium contrast is eliminated from the body
by the kidneys, so a test of kidney function must be performed prior to participation in this study,
and any patients with kidney problems will be excluded. In clinical trials, the most commonly
reported adverse reactions to contrast in adults were headache and nausea. Less common
reactions include vomiting, feeling hot, an allergic reaction at the injection site, distorted sense of
taste, sensation of tingling, pricking or numbness, dizziness, rash or increased blood
pressure. Some patients with severe or acute kidney impairment have developed a condition
called nephrogenic systemic fibrosis (NSF) from receiving gadolinium contrast, a condition that may
be fatal. You will be assessed for safety to receive this contrast agent. People with allergies, or known
sensitivities to contrast agents similar to gadolinium are at increased risk for more
serious side effects, and therefore will not be allowed to participate in this study. No toxic effects
on the brain have been reported with repeated use of this type of contrast.
You will be also injected with another contrast agent called particle Ferumoxytol (Feraheme®). Risks
of the intravenous injection include bleeding or bruising, and very rarely, infection. No higher risks of
Ferumoxytol than gadolinium-based contrast agent have been reported. We will use slow infusion
rather than bolus injection for this study. Although it has not been approved as a contrast agent for
MRI, it has been extensively used in human MRI research. There are more than 820 publications
related to its use since 2009 (when the agent was approved for human use). Ferumoxytol is safe in
patients with chronic kidney disease since it is cleared from the circulation primarily by the
reticuloendothelial system instead of the kidney. We will use a very low dose of Ferumoxytol (2.6
mg/kg for any given injection) in our human studies injected over 15 minutes. Our approach, using a
low dose combined with a long injection time, is much safer than what is currently used. In rare
instances, Ferumoxytol has been known to cause serious hypersensitivity reactions, including
anaphylaxis and/or anaphylactoid reactions. In the clinical studies of Ferumoxytol, serious
hypersensitivity reactions were reported in 0.2% (3/1726) of subjects receiving Ferumoxytol. Other
adverse reactions potentially associated with hypersensitivity (e.g. pruritus, rash, urticaria or wheezing)
were reported in 3.7% (63/1726) of these subjects.
As a result of your participation in this study you will be exposed to radiation from the PET scan.
Please note that this radiation is not necessary for your medical care and is for research purposes only.
The amount of radiation exposure you will receive from participation in this study is estimated to be
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 7 of 12
approximately 10 milliSieverts (mSv) or less over 18 months. A mSv is a unit of radiation dose. For
comparison, everyone receives radiation exposure from natural background sources from the earth and
the sky. The dose that you could receive from participation in this research study is about the same as
you would normally receive in 3-4 years from these natural sources. Scientists disagree on whether
radiation doses at these levels are harmful. A possible effect that could occur at doses associated with
this study is a slight increase in the risk of developing cancer later in life.
If you are a woman who can become pregnant, you must have a negative blood pregnancy test before
the research PET and MRI scan. Aside from the risk of radiation exposure, there are no known risks.
Putting in an IV catheter can cause pain, bleeding, or bruising at the place where the needle
enters the vein. There is a very small risk of an infection or a bruise at the spot where we place the IV
catheter. We will treat an infection with antibiotics. Bruises usually go away without treatment.
You will feel a small pinch or have some bruising when you have the blood drawn.
There are no known risks associated with the clinical testing (walk, OCT, blood pressure, weight, etc.),
physical, neurological, or cognitive assessments.
What happens to the information collected for the research?
Efforts will be made to limit the use and disclosure of your personal information, including research
study and medical or education records, to people who have a need to review this information. We
cannot promise complete secrecy. Organizations that may inspect and copy your information include
the IRB and other representatives of this organization
Federal law provides additional protections of your medical records and related health information.
These are described in the HIPAA section of this document.
If identifiers are removed from your identifiable private information, or identifiable samples that are
collected during this research, that information or those samples could be used for future research
studies or distributed to another investigator for future research studies without your additional
informed consent.
Can I be removed from the research without my OK?
The principal investigator of the study can remove you from the research study without your approval.
Possible reasons for removal include an inability to complete the MRI or an indication that it would be
unsafe for you to do so, or pregnancy. In order to ensure against pregnancy, participants are asked to
use approved contraceptives for the duration of the study.
We will tell you about any new information that may affect your health, welfare, or choice to stay in
the research.
What else do I need to know?
Who is paying for this research?
This research is being funded by Novartis, but is sponsored by the University at Buffalo.
What medical costs am I responsible for paying?
The tests or procedures required by the research study that would not otherwise be part of your
standard care will be covered by the sponsor of this study. The tests or procedures that would be
provided to any patient with your condition, regardless of whether he/she was participating in the
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 8 of 12
research study, are considered standard care and will be billed to you or your private or public health
insurance company. You will still be responsible for the cost of your usual ongoing medical care,
including deductibles and co-payments. If you have any questions about what expenses are covered by
the sponsor and what expenses are the responsibility of you or your health insurance provider, please
contact a member of the study staff and/or your health insurance provider.
Who will pay for my medical care if participating in this research harms me?
It is important that you tell your study doctor if you feel that taking part in this study has injured you or
caused you to become ill.
You will receive medical treatment if you are injured or become ill as a result of this study. Your
doctor will explain the treatment options to you and tell you where you can get treatment.
The University at Buffalo and the Buffalo Neuroimaging Analysis Center (BNAC) makes no
commitment to provide free medical care or payment for any unfavorable outcomes that result from
your participation in this research. Medical services will be billed at the usual charge and will be your
responsibility or that of your third-party payer but you are not precluded from seeking to collect
compensation for injury related to malpractice, fault, or blame on the part of those involved in the
research including (BNAC) and the University at Buffalo. The sponsor of the study is not providing
subject injury coverage.
By accepting medical care or accepting payment for medical expenses, you are not waiving any of
your legal rights.
Will I get paid for my participation in this research
If you agree to take part in this research study, we will pay you for your time and effort.

If you complete the clinical visit, you will be paid $50

If you complete a PET scan, you will be paid $100 per PET scan

If you complete the planned MRI scan over day one, you will be paid $50 and if you complete
both MRIs over 2 days, you will be paid $100
The total amount you may receive for taking part at every time point visit and completing the study is
$1,250. You will be paid by check which will be mailed to you after each visit. If you have to stop any
procedure of the study visit early for any purpose, you will still receive compensation for your time, as
above. We will also pay UBER to transport you from home to testing and back for each MRI, PET and
clinical visit.
Payments that you receive for your participation in this research are considered taxable income. If the
amount of payment that you receive reaches or exceeds $600.00 in a calendar year, you will be issued a
1099 form.
What are my alternatives to participating in this research study?
Instead of being in this research study, you can choose to not participate.
What will happen to my information and samples?
Your information and samples (both identifiable and de-identified) may be used to create products or
to deliver services, including some that may be sold and/or make money for others. If this happens,
there are no plans to tell you, or to pay you, or to give any compensation to you or your family.
What will I be told about clinically relevant research results?
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 9 of 12
Most tests done on samples in research studies are only for research purposes and have no clear
meaning for health care. If the research with your identifiable information or samples gives results that
do have meaning for your health, the PI of the study will notify your personal care physician who will
contact you to let you know what we have found. If the researchers return genetic test results to you, it
may be because they think you could have a health risk and want to recommend that the test should be
re-done by a certified clinical laboratory to check the results. If this happens, then you may want to get
a second test from a certified clinical laboratory, consult your own doctor, or get professional genetic
counseling. You may have to pay for those additional services yourself.
HIPAA: Authorization for the Use and Disclosure of Identifiable Health
Information for Research Purposes This section describes information about you
and about your health that will be obtained by the researchers when you participate in the research
study. Health information is considered "protected health information" when it may directly
identify you as an individual. By signing this form you are agreeing to permit the researchers
and/or other parties (described in detail below) to have access to this information. If there are any
parts of this form that you do not understand, please be sure to ask us for further clarification.
A. What protected health information will be collected about you as part of this research
study?
X
Information from your full medical records. This includes information related to the
clinical, neurological, and/or physical evaluations for this study.
X
New Health Information created from study related tests, procedures, visits, and/or
questionnaires as described in this consent form.
B.
Who is authorized to provide or collect this information?
X
Principal Investigator or designee
C. With whom may your protected health information be shared?
Your health information may be shared with others outside of the research group for purposes
directly related to the conduct of this research study or as required by law, including but not
limited to:
X
Clinical staff not involved in this research study who may become involved in your
care if it is potentially relevant to your treatment
X
The sponsor of this research study, Novartis, cooperative group, etc., or its agents
X
The organization(s) responsible for administering this research: SUNY Buffalo’s
Research Foundation
Your information may also be shared with individuals or entities responsible for general
administration, oversight and compliance of research activities. Examples of this include the
institution's Privacy and Security Officers or other internal oversight staff, Safety Monitoring
Boards, an Institutional Review Board, The Research Foundation of the State University of
New York, University at Buffalo Foundation Services, and accrediting bodies, or with certain
government oversight agencies that have authority over the research including the Department
of Health and Human Services (HHS), the Food and Drug Administration (FDA), the National
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 10 of 12
Institutes of Health (NIH), and the Office of Human Research Protections (OHRP). Your
information may also be shared with other entities as permitted or required by law. All
reasonable efforts will be used to protect the confidentiality of your individually identifiable
health information that may be shared with others as described above.
All reasonable efforts will be used to protect the confidentiality of your protected health
information. There is the potential for individually identifiable information and the associated
health information obtained with this authorization to be re-disclosed by the recipient(s). After
such a disclosure, the information may no longer be protected by the terms of this authorization
against further re-disclosure.
D. How long will this information be kept by the Principal Investigator?
X
a. This authorization has no expiration date. The researchers may continue to rely on
this authorization to obtain and use protected health information about you unless you
revoke this authorization in writing.
X
d. Your protected health information will go into a database that will be maintained
indefinitely. Any future study using this information that falls outside the scope of
this current study will be required to follow guidelines designed to govern access to
that information and to protect the privacy of that information.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 11 of 12
E. What are your rights after signing this authorization?
You have the right to revoke this authorization at any time. If you withdraw your authorization,
no additional efforts to collect individually identifiable health information about you will be
made. You should know, however, that protected health information acquired using this
authorization prior to its withdrawal may continue to be used to the extent that the
investigator(s) have already relied on your permission to conduct the research. If you chose to
withdraw this authorization, you must do so in writing to the following individual(s):
Robert Zivadinov, MD
Department of Neurology
Buffalo Neuroimaging Analysis Center
D-2
100 High St., Buffalo, NY, 14203
716-859-7040
If you send us a request to withdraw your authorization, we will forward that request to the
institutions we have shared it with in order to collect your individually identifiable health
information.
F. What will happen if you decide not to sign this authorization?
Refusing to sign this authorization will not affect the present or future care you receive at this
institution and will not cause any penalty or loss of benefits to which you are otherwise
entitled. If you decide not to sign this authorization, you will not be able to participate in the
research study.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 12 of 12
Signature Block for Capable Adult
Your signature documents your permission to take part in this research. By signing this form you are
not waiving any of your legal rights, including the right to seek compensation for injury related to
negligence or misconduct of those involved in the research.
Signature of subject
Date
Printed name of subject
Signature of person obtaining consent
Date
Printed name of person obtaining consent
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 1 of 10
University at Buffalo Institutional Review Board (UBIRB)
Office of Research Compliance | Clinical and Translational Research Center Room 5018
875 Ellicott St. | Buffalo, NY 14203
UB Federalwide Assurance ID#: FWA00008824
Adult Consent to Participate in a Research Study as a Healthy Participant
Title of research study: Open-label, single-blinded, observational, prospective, 36-month,
longitudinal, controlled study to assess the efficacy of siponimod (Mayzent®) on microglia in
patients with secondary progressive forms of multiple sclerosis
Version Date: 30Sep22
Investigator: Robert Zivadinov, MD, PhD
Key Information: The following is a short summary of this study to help you decide whether or
not to be a part of this study. More detailed information is listed later on in this form.
Why am I being invited to take part in a research study?
You are being invited to take part in a research study because you are a healthy individual without
multiple sclerosis (MS) or any other neurological disorders (OND).
What should I know about a research study?

Someone will explain this research study to you.

Whether or not you take part is up to you.

You can choose not to take part.

You can agree to take part and later change your mind.

Your decision will not be held against you.

You can ask all the questions you want before you decide.
Why is this research being done?
The purpose of this research is to examine the association between the development of microglia-
related pathology using positron emission tomography (PET) and magnetic resonance imaging (MRI)
in secondary progressive MS patients being treated with Mayzent or Ocrevus. Microglia is a type of
cell found in the brain and spinal cord that is involved in the pathogenesis of multiple sclerosis (MS).
Greater activation of these cells is related to development of secondary progressive MS, but it is
unknown whether there is an effect of currently available MS treatments on these types of cells.
Therefore, this research will use advanced imaging techniques to answer this important question using
two commonly available, FDA approved, MS treatments.
We are asking healthy controls to participate so that we can validate the choice of the reference region
of the brain being studied in MS patients.
How long will the research last and what will I need to do?
We expect that you will be in this research study for about 4 hours.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 2 of 10
You will be asked to have one MRI exam, one PET scan, 1 physical exam and a demographic
questionnaire. You will also be asked to complete a brief questionnaire to ensure it is safe for you to
have an MRI.
More detailed information about the study procedures can be found under “What happens if I say yes,
I want to be in this research?”
Is there any way being in this study could be bad for me?
Pregnant women will not be eligible to participate in this study.
During the MRI exam, you will be lying on your back. You may experience discomfort from lying
still during the exam, or mild claustrophobia. To reduce discomfort, a cushion will be placed under
your knees. Your head will be resting on a device called a head coil, which is necessary to collect the
images. When images are being acquired, the MRI scanner produces continuous loud noise, which
sounds like rapid hammering. You will be given ear plugs to help block out the sound of the MRI
scanner. You may be offered headphones to listen to music during your scan. There is a microphone
and a speaker in the MRI scanner, so you will be able to talk to the MRI technologist between scans.
You will also be given a ‘call ball’ to hold in your hand during the exam that you can use if you
urgently need to stop the exam.
During the PET scan, you will be exposed to radiation and during MRI of injection of Ferumoxytol.
Please note that this radiation is not necessary for your medical care and is for research purposes only.
During the insertion of the IVs (MRI and PET) you may experience a little pain at the site, some
bruising and redness. Allergic reactions are very rare. However, there could be some itchy, redness at
the injection site. You will not be given a contrast agent for the MRI.
There are no known risks associated with the physical or completion of the demographic questionnaire.
More detailed information about the risks of this study can be found under “Is there any way being in
this study could be bad for me? (Detailed Risks)”
Will being in this study help me in any way?
There are no benefits to you from your taking part in this research. We cannot promise any benefits to
others from your taking part in this research. However, possible benefits to others include better
understanding of the interaction between cell components and other biological and clinical factors.
What happens if I do not want to be in this research?
Participation in research is completely voluntary. You may choose not to enroll in this study. Your
alternative to participating in this research study is to not participate.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 3 of 10
Detailed Information: The following is more detailed information about this study in
addition to the information listed above.
Who can I talk to?
If you have questions, concerns, or complaints, or think the research has hurt you, talk to the research
team at rzivadinov@bnac.net. You may also contact the research participant advocate at 716-888-4845
or researchadvocate@buffalo.edu.
This research has been reviewed and approved by an Institutional Review Board (“IRB”). You may
talk to them at (716) 888-4888 or email ub-irb@buffalo.edu
if:

You have questions about your rights as a participant in this research

Your questions, concerns, or complaints are not being answered by the research team.

You cannot reach the research team.

You want to talk to someone besides the research team.

You want to get information or provide input about this research.
How many people will be studied?
We expect to recruit 15 healthy controls in this research study.
What happens if I say yes, I want to be in this research?
If you take part in this research, you will be asked to have one MRI exam and one PET scan.
Genotyping for the DNA polymorphism of the TSPO gene on chromosome 22q13.2 SNP:
All subjects will be genotyped for the DNA polymorphism of the TSPO gene on chromosome 22q13.2.
This test allows us to determine the eligibility of each subject to proceed in the study. The information
regarding these genes allows us to determine your ability to interface with the injected molecules. This
procedure allows comparing subjects despite their different genetic background.
MRI
The MRI will happen at Buffalo General Hospital on the 1st floor. The duration of MRI is
approximately 40 min and we will book additional 10 minutes for your positioning/removal into/from
the scanner. Therefore, the total MRI protocol will be approximately of 50 min duration.
During the MRI procedure, you will be asked to lie on your back in the MRI machine. The MRI
machine is a small tunnel into which you will be inserted. You will lie on your back and cannot move
for the duration of testing. You will have a call button with which you can communicate with the
technician performing the test. The MRI can produce loud knocking sounds. You can use ear plugs to
reduce the noise if you wish.
PET
The use of PET in this study will be done only for research purposes, to study microglia activation in
the brain. During the research PET procedure, you will lie down on a padded table with your head in a
special rest position so that you can stay still throughout the scan. You will then have an IV placed
into your arm or hand in order to inject a tracer agent or dye typically used in routine PET scanning.
During this procedure you will have 2 blood draws (about 4 teaspoons). The whole PET session will
last approximately 120 min. You will be given the opportunity to take a break for up to 15 minutes
after 50 minutes of scanning, following which the last 60 minutes of scanning will be completed.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 4 of 10
The scanner is very quiet. You can also listen to music or sleep during the scan. You will be asked to
drink plenty of water before and after the scan to help flush the dye out of your system after scanning.
MRI Pre-Screen Questionnaire
You will be asked questions about certain types of medical procedures and implants that may make it
unsafe for you to complete an MRI. This questionnaire will take roughly 15 minutes to complete.
A small amount of blood will be drawn (approximately 2 tablespoons). This will be used for research
purpose of investigating experimental biomarkers related to microglia activity in the blood.
Physical Examination: You will see a clinician for your physical assessments. This visit is routine in
nature in that it should mimic your usual appointments that you would have with your primary care
physician.
Demographic Questionnaire: There are a few questions regarding date of birth, gender, race, ethnicity
and hand dominance.
What are my responsibilities if I take part in this research?
We ask that you are honest in your responses during testing throughout the study. If you are
uncomfortable with any question or procedure, you can stop and voluntarily stop participation with no
penalty nor any change to your routine clinical care.
What happens if I say yes, but I change my mind later?
You can leave the research at any time. It will not be held against you.
Is there any way being in this study could be bad for me? (Detailed Risks)
During the MRI exam, you will be lying on your back. You may experience discomfort from lying
still during the exam, or mild claustrophobia. To reduce discomfort, a cushion will be placed under
your knees. Your head will be resting on a device called a head coil, which is necessary to collect the
images. When images are being acquired, the MRI scanner produces continuous loud noise, which
sounds like rapid hammering. You will be given ear plugs to help block out the sound of the MRI
scanner. You may be offered headphones to listen to music during your scan. There is a microphone
and a speaker in the MRI scanner, so you will be able to talk to the MRI technologist between scans.
You will also be given a ‘call ball’ to hold in your hand during the exam that you can use if you
urgently need to stop the exam. The MRI has a potential, during normal use to cause localized
warming of your skin and the underlying tissues. You should immediately inform us if you experience
discomfort due to warming and the procedure will be stopped.
As a result of your participation in this study you will be exposed to radiation from the PET scan.
Please note that this radiation is not necessary for your medical care and is for research purposes only.
The amount of radiation exposure you will receive from participation in this study is estimated to be
approximately 10 milliSieverts (mSv) or less over 18 months. A mSv is a unit of radiation dose. For
comparison, everyone receives radiation exposure from natural background sources from the earth and
the sky. The dose that you could receive from participation in this research study is about the same as
you would normally receive in 3-4 years from these natural sources. Scientists disagree on whether
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 5 of 10
radiation doses at these levels are harmful. A possible effect that could occur at doses associated with
this study is a slight increase in the risk of developing cancer later in life.
You will be injected with a contrast agent called particle Ferumoxytol (Feraheme®). Risks of the
intravenous injection include bleeding or bruising, and very rarely, infection. No higher risks of
Ferumoxytol than gadolinium-based contrast agent have been reported. We will use slow infusion
rather than bolus injection for this study. Although it has not been approved as a contrast agent for
MRI, it has been extensively used in human MRI research. There are more than 820 publications
related to its use since 2009 (when the agent was approved for human use). Ferumoxytol is safe in
patients with chronic kidney disease since it is cleared from the circulation primarily by the
reticuloendothelial system instead of the kidney. We will use a very low dose of Ferumoxytol (2.6
mg/kg for any given injection) in our human studies injected over 15 minutes. Our approach, using a
low dose combined with a long injection time, is much safer than what is currently used. In rare
instances, Ferumoxytol has been known to cause serious hypersensitivity reactions, including
anaphylaxis and/or anaphylactoid reactions. In the clinical studies of Ferumoxytol, serious
hypersensitivity reactions were reported in 0.2% (3/1726) of subjects receiving Ferumoxytol. Other
adverse reactions potentially associated with hypersensitivity (e.g. pruritus, rash, urticaria or wheezing)
were reported in 3.7% (63/1726) of these subjects.
If you are a woman who can become pregnant, you must have a negative blood pregnancy test before
the research PET and MRI scan. Aside from the risk of radiation exposure, there are no known risks.
Putting in an IV catheter can cause pain, bleeding, or bruising at the place where the needle
enters the vein. There is a very small risk of an infection or a bruise at the spot where we place the IV
catheter. We will treat an infection with antibiotics. Bruises usually go away without treatment.
You will feel a small pinch or have some bruising when you have the blood drawn.
What happens to the information collected for the research?
Efforts will be made to limit the use and disclosure of your personal information, including research
study and medical or education records, to people who have a need to review this information. We
cannot promise complete secrecy. Organizations that may inspect and copy your information include
the IRB and other representatives of this organization
Federal law provides additional protections of your medical records and related health information.
These are described in the HIPAA section of this document.
If identifiers are removed from your identifiable private information, or identifiable samples that are
collected during this research, that information or those samples could be used for future research
studies or distributed to another investigator for future research studies without your additional
informed consent.
Can I be removed from the research without my OK?
The principal investigator of the study can remove you from the research study without your approval.
Possible reasons for removal include an inability to complete the MRI or an indication that it would be
unsafe for you to do so, or pregnancy. In order to ensure against pregnancy, participants are asked to
use approved contraceptives for the duration of the study.
We will tell you about any new information that may affect your health, welfare, or choice to stay in
the research.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 6 of 10
What else do I need to know?
Who is paying for this research?
This research is being funded by Novartis, but is sponsored by the University at Buffalo.
What medical costs am I responsible for paying?
The tests or procedures required by the research study that would not otherwise be part of your
standard care will be covered by the sponsor of this study. You will still be responsible for the cost of
your usual ongoing medical care, including deductibles and co-payments. If you have any questions
about what expenses are covered by the sponsor and what expenses are the responsibility of you or
your health insurance provider, please contact a member of the study staff and/or your health insurance
provider.
Who will pay for my medical care if participating in this research harms me?
It is important that you tell the study team if you feel that taking part in this study has injured you or
caused you to become ill.
You will receive medical treatment if you are injured or become ill as a result of this study. Your
doctor will explain the treatment options to you and tell you where you can get treatment.
The University at Buffalo and the Buffalo Neuroimaging Analysis Center (BNAC) makes no
commitment to provide free medical care or payment for any unfavorable outcomes that result from
your participation in this research. Medical services will be billed at the usual charge and will be your
responsibility or that of your third-party payer but you are not precluded from seeking to collect
compensation for injury related to malpractice, fault, or blame on the part of those involved in the
research including (BNAC) and the University at Buffalo. The sponsor of the study is not providing
subject injury coverage.
By accepting medical care or accepting payment for medical expenses, you are not waiving any of
your legal rights.
Will I get paid for my participation in this research
If you agree to take part in this research study, we will pay you for your time and effort.
You will be compensated $250 for completion of the MRI, PET and physical exams and completion of
the questionnaires.
You will be paid by check which will be mailed to you after each visit. If you have to stop any procedure
of the study visit early for any purpose, you will still receive compensation for your time, as above. We
will also pay UBER to transport you from home to testing for the MRI and PET exams.
Payments that you receive for your participation in this research are considered taxable income. If the
amount of payment that you receive reaches or exceeds $600.00 in a calendar year, you will be issued a
1099 form.
What are my alternatives to participating in this research study?
Instead of being in this research study, you can choose to not participate.
What will happen to my information and samples?
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 7 of 10
Your information and samples (both identifiable and de-identified) may be used to create products or
to deliver services, including some that may be sold and/or make money for others. If this happens,
there are no plans to tell you, or to pay you, or to give any compensation to you or your family.
What will I be told about clinically relevant research results?
Most tests done on samples in research studies are only for research purposes and have no clear
meaning for health care. If the research with your identifiable information or samples gives results that
do have meaning for your health, the PI of the study will notify your personal care physician who will
contact you to let you know what we have found. If the researchers return genetic test results to you, it
may be because they think you could have a health risk and want to recommend that the test should be
re-done by a certified clinical laboratory to check the results. If this happens, then you may want to get
a second test from a certified clinical laboratory, consult your own doctor, or get professional genetic
counseling. You may have to pay for those additional services yourself.
HIPAA: Authorization for the Use and Disclosure of Identifiable Health
Information for Research Purposes This section describes information about you
and about your health that will be obtained by the researchers when you participate in the research
study. Health information is considered "protected health information" when it may directly
identify you as an individual. By signing this form you are agreeing to permit the researchers
and/or other parties (described in detail below) to have access to this information. If there are any
parts of this form that you do not understand, please be sure to ask us for further clarification.
A. What protected health information will be collected about you as part of this research
study?
X
Name, gender, date of birth
X
New Health Information created from study related tests, procedures, visits, and/or
questionnaires as described in this consent form.
B.
Who is authorized to provide or collect this information?
X
Principal Investigator or designee
C. With whom may your protected health information be shared?
Your health information may be shared with others outside of the research group for purposes
directly related to the conduct of this research study or as required by law, including but not
limited to:
X
Clinical staff not involved in this research study who may become involved in your
care if it is potentially relevant to your treatment
X
The sponsor of this research study, Novartis, cooperative group, etc., or its agents
X
The organization(s) responsible for administering this research: SUNY Buffalo’s
Research Foundation
Your information may also be shared with individuals or entities responsible for general
administration, oversight and compliance of research activities. Examples of this include the
institution's Privacy and Security Officers or other internal oversight staff, Safety Monitoring
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 8 of 10
Boards, an Institutional Review Board, The Research Foundation of the State University of
New York, University at Buffalo Foundation Services, and accrediting bodies, or with certain
government oversight agencies that have authority over the research including the Department
of Health and Human Services (HHS), the Food and Drug Administration (FDA), the National
Institutes of Health (NIH), and the Office of Human Research Protections (OHRP). Your
information may also be shared with other entities as permitted or required by law. All
reasonable efforts will be used to protect the confidentiality of your individually identifiable
health information that may be shared with others as described above.
All reasonable efforts will be used to protect the confidentiality of your protected health
information. There is the potential for individually identifiable information and the associated
health information obtained with this authorization to be re-disclosed by the recipient(s). After
such a disclosure, the information may no longer be protected by the terms of this authorization
against further re-disclosure.
D. How long will this information be kept by the Principal Investigator?
X
a. This authorization has no expiration date. The researchers may continue to rely on
this authorization to obtain and use protected health information about you unless you
revoke this authorization in writing.
X
d. Your protected health information will go into a database that will be maintained
indefinitely. Any future study using this information that falls outside the scope of
this current study will be required to follow guidelines designed to govern access to
that information and to protect the privacy of that information.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 9 of 10
E. What are your rights after signing this authorization?
You have the right to revoke this authorization at any time. If you withdraw your authorization,
no additional efforts to collect individually identifiable health information about you will be
made. You should know, however, that protected health information acquired using this
authorization prior to its withdrawal may continue to be used to the extent that the
investigator(s) have already relied on your permission to conduct the research. If you chose to
withdraw this authorization, you must do so in writing to the following individual(s):
Robert Zivadinov, MD
Department of Neurology
Buffalo Neuroimaging Analysis Center
D-2
100 High St., Buffalo, NY, 14203
716-859-7040
If you send us a request to withdraw your authorization, we will forward that request to the
institutions we have shared it with in order to collect your individually identifiable health
information.
F. What will happen if you decide not to sign this authorization?
Refusing to sign this authorization will not affect the present or future care you receive at this
institution and will not cause any penalty or loss of benefits to which you are otherwise
entitled. If you decide not to sign this authorization, you will not be able to participate in the
research study.
IRB Approval Period:
9/29/2022 - 9/28/2023


Permission to Take Part in a Human Research Study
HRPP Revision Date: October 2, 2019
Page 10 of 10
Signature Block for Capable Adult
Your signature documents your permission to take part in this research. By signing this form you are
not waiving any of your legal rights, including the right to seek compensation for injury related to
negligence or misconduct of those involved in the research.
Signature of subject
Date
Printed name of subject
Signature of person obtaining consent
Date
Printed name of person obtaining consent
IRB Approval Period:
9/29/2022 - 9/28/2023